Physician profile
Catherine Ann Miller
NPI 1972295038
$4,385.10
in general payments reported to CMS, 2019-2025
19 companies · $2,387 in 2025
The $2,387 reported for 2025 was more than what 90% of Psychiatric/Mental Health (Clinical Nurse Specialist) providers received nationally (typical 2025 total: $244).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $437 · 2024: $1,561 · 2025: $2,387.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,162 · Education: $223.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,162.12 |
| Education | $222.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,423.37 | 2023-2025 | |
| Otsuka America Pharmaceutical, INC. | $1,091.06 | 2024-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Teva Pharmaceuticals USA, INC. | $583.99 | 2023-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Alkermes, INC. | $281.49 | 2023-2025 | Aristada, Lybalvi, Vivitrol |
| E.R. Squibb & Sons, L.L.C. | $272.67 | 2025 | Cobenfy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $149.14 | 2024-2025 | Caplyta |
| Supernus Pharmaceuticals, INC. | $84.91 | 2024-2025 | Qelbree |
| Lundbeck LLC | $73.60 | 2024-2025 | Rexulti, Abilify Maintena |
| Almatica Pharma LLC | $70.83 | 2024 | Loreev Xr |
| Axsome Therapeutics, INC. | $64.82 | 2024-2025 | Auvelity, Sunosi |
| Vanda Pharmaceuticals INC. | $64.33 | 2024-2025 | Hetlioz, Fanapt |
| Collegium Pharmaceutical, INC. | $47.29 | 2025 | Jornay Pm |
| Tris Pharma INC | $42.98 | 2024-2025 | Dyanavel Xr |
| Janssen Pharmaceuticals, INC | $42.65 | 2025 | Spravato |
| Indivior INC. | $24.14 | 2025 | Sublocade |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $20.75 | 2024 | Azstarys |
| Hologic Sales and Service, LLC | $16.43 | 2024 | Aptima |
| Idorsia Pharmaceuticals US INC | $15.49 | 2024 | Quviviq |
| Neuronetics, INC. | $15.16 | 2025 | Neurostar Tms Therapy System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Catherine Miller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.